Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Dupilumab for treating severe asthma

Published: 8 December 2021
Asthma patient
Severe asthma is a distressing and socially isolating condition

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Dupilumab as a possible additional treatment for severe asthma with type 2 inflammation. The guidance was informed by a report produced by SHTAC.

NICE’s guidance recommends Dupilumab as a possible additional treatment for severe asthma with type 2 inflammation. It is available for people 12 years and over with asthma that is inadequately controlled despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, if:

  • the dosage used is 400 mg initially and then 200 mg every other week subcutaneously
  • the person has agreed to and follows a treatment plan
  • blood eosinophil levels are 150 cells per microlitre or more and fractional exhaled nitric oxide is 25 parts per billion or more, and there have been at least 4 episodes of worse asthma in the past 12 months
  • the person is not eligible for mepolizumab, resilizumab or benralizumab, or has asthma that has not responded well enough to these biological therapies.
  • Dupliumab can only be used for longer than 12 months if it is working well.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research on asthma please visit our Research page.

Privacy Settings